{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T00:28:20Z","timestamp":1783211300365,"version":"3.54.6"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T00:00:00Z","timestamp":1673049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T00:00:00Z","timestamp":1673049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Impaired renal function is frequently observed in patients with heart failure and reduced ejection fraction (HFrEF). The differential effect of sacubitril\/valsartan and angiotensin-converting enzyme inhibitors\/angiotensin-receptor blockers (ACEIs\/ARBs) on the clinical and renal outcomes in patients with HFrEF and chronic kidney disease (CKD) remains unknown.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aims<\/jats:title>\n                <jats:p>This study aimed to explore the differential effect of sacubitril\/valsartan and ACEI\/ARB on the clinical and renal outcomes as well as renal function over a 12-month follow-up period in HFrEF patients with and without CKD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with HfrEF (LVEF \u226435%) and NYHA class \u2265II were enrolled from the Chang Gung Research Database between 2017 and 2020. Baseline characteristics were compared between patients prescribed sacubitril\/valsartan and ACEI\/ARB. After propensity score matching, the following clinical and renal outcomes were compared between the two groups in patients with and without CKD over a 12-month follow-up period: acute kidney injury (AKI), emergent dialysis\/renal death, HF hospitalization, cardiovascular mortality, and all-cause mortality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>This study enrolled 3735 HFrEF patients with a mean left ventricular EF of 27.56 \u00b1 5.86%, who had been prescribed sacubitril\/valsartan (N = 1708) or ACEI\/ARB (N = 2027). After propensity score matching, the clinical and renal outcomes did not differ between the sacubitril\/valsartan and ACEI\/ARB groups in patients without CKD. In patients with CKD, the ACEI\/ARB group had a significantly higher incidence of all-cause mortality than the sacubitril\/valsartan group (14.89% vs. 10.50%; hazard ratio 1.46; 95% confidence interval 1.06\u20132.00; <jats:italic>p<\/jats:italic> = 0.02), and the incidence of AKI, HF hospitalization, and CV mortality did not differ between the two groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Sacubitril\/valsartan had a lower all-cause mortality compared to ACEI\/ARB in symptomatic HFrEF patients with CKD. Further prospective randomized studies are warranted to confirm our findings.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10557-022-07421-0","type":"journal-article","created":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T06:04:01Z","timestamp":1673071441000},"page":"505-515","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Sacubitril\/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0585-6134","authenticated-orcid":false,"given":"Wei-Chieh","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Wei","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiu-Yu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Nan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huang-Chung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Sheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang-Hung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mien-Cheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,7]]},"reference":[{"key":"7421_CR1","doi-asserted-by":"publisher","first-page":"112","DOI":"10.2174\/1573403X11309020004","volume":"9","author":"Y Guo","year":"2013","unstructured":"Guo Y, Lip GY, Banerjee A. Heart failure in East Asia. Curr Cardiol Rev. 2013;9:112\u201322.","journal-title":"Curr Cardiol Rev"},{"key":"7421_CR2","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","volume":"316","author":"CONSENSUS Trial Study Group","year":"1987","unstructured":"CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429\u201335.","journal-title":"N Engl J Med"},{"key":"7421_CR3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"S Yusuf","year":"1991","unstructured":"SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293\u2013302.","journal-title":"N Engl J Med"},{"key":"7421_CR4","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1056\/NEJMoa010713","volume":"345","author":"JN Cohn","year":"2001","unstructured":"Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667\u201375.","journal-title":"N Engl J Med"},{"key":"7421_CR5","first-page":"e876","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e876\u2013e94.","journal-title":"Circulation"},{"key":"7421_CR6","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, ESC Scientific Document Group, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599\u2013726.","journal-title":"Eur Heart J"},{"key":"7421_CR7","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993\u20131004.","journal-title":"N Engl J Med"},{"key":"7421_CR8","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1001\/jama.2019.12843","volume":"322","author":"AS Desai","year":"2019","unstructured":"Desai AS, Solomon SD, Shah AM, et al. EVALUATE-HF Investigators. Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2019;322:1077\u201384.","journal-title":"JAMA"},{"key":"7421_CR9","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895\u2013e1032.","journal-title":"Circulation"},{"key":"7421_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10741-019-09870-6","volume":"25","author":"G Ruocco","year":"2020","unstructured":"Ruocco G, Palazzuoli A, Ter Maaten JM. The role of the kidney in acute and chronic heart failure. Heart Fail Rev. 2020;25:107\u201318.","journal-title":"Heart Fail Rev"},{"key":"7421_CR11","doi-asserted-by":"publisher","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","volume":"139","author":"J Rangaswami","year":"2019","unstructured":"Rangaswami J, Bhalla V, Blair JEA, et al. American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Clinical Cardiology. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019;139:e840\u2013e78.","journal-title":"Circulation"},{"key":"7421_CR12","doi-asserted-by":"publisher","first-page":"3239057","DOI":"10.1155\/2022\/3239057","volume":"2022","author":"K Ma","year":"2022","unstructured":"Ma K, Gao W, Xu H, Liang W, Ma G. Role and mechanism of the renin-angiotensin-aldosterone system in the onset and development of cardiorenal syndrome. J Renin-Angiotensin-Aldosterone Syst. 2022;2022:3239057.","journal-title":"J Renin-Angiotensin-Aldosterone Syst"},{"key":"7421_CR13","doi-asserted-by":"crossref","unstructured":"Chapter 1: Definition and classification of CKD. Kidney Int Suppl (2011). 2013;3:19-62.","DOI":"10.1038\/kisup.2012.64"},{"key":"7421_CR14","doi-asserted-by":"publisher","first-page":"555","DOI":"10.23876\/j.krcp.21.900","volume":"40","author":"IJ Cho","year":"2021","unstructured":"Cho IJ, Kang SM. Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease. Kidney Res Clin Pract. 2021;40:555\u201365.","journal-title":"Kidney Res Clin Pract"},{"key":"7421_CR15","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jphs.2019.09.014","volume":"142","author":"A Rahman","year":"2020","unstructured":"Rahman A, Sherajee SJ, Rafiq K, et al. The angiotensin II receptor-neprilysin inhibitor LCZ696 attenuates the progression of proteinuria in type 2 diabetic rats. J Pharmacol Sci. 2020;142:124\u20136.","journal-title":"J Pharmacol Sci"},{"key":"7421_CR16","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1097\/HJH.0000000000002326","volume":"38","author":"E Uijl","year":"2020","unstructured":"Uijl E, \u2019t Hart DC, Roksnoer LCW, et al. Angiotensin-neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury. J Hypertens. 2020;38:755\u201364.","journal-title":"J Hypertens"},{"key":"7421_CR17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.lfs.2019.02.027","volume":"221","author":"V Malek","year":"2019","unstructured":"Malek V, Sharma N, Sankrityayan H, Gaikwad AB. Concurrent neprilysin inhibition and renin-angiotensin system modulations prevented diabetic nephropathy. Life Sci. 2019;221:159\u201367.","journal-title":"Life Sci"},{"key":"7421_CR18","doi-asserted-by":"publisher","first-page":"173444","DOI":"10.1016\/j.ejphar.2020.173444","volume":"884","author":"H Kang","year":"2020","unstructured":"Kang H, Zhang J, Zhang X, et al. Effects of sacubitril\/valsartan in patients with heart failure and chronic kidney disease: a meta-analysis. Eur J Pharmacol. 2020;884:173444.","journal-title":"Eur J Pharmacol"},{"key":"7421_CR19","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","volume":"6","author":"K Damman","year":"2018","unstructured":"Damman K, Gori M, Claggett B, et al. Renal effects and associated outcomes during Aangiotensin-neprilysin inhibition in heart failure. JACC Heart Fail. 2018;6:489\u201398.","journal-title":"JACC Heart Fail"},{"key":"7421_CR20","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","volume":"138","author":"R Haynes","year":"2018","unstructured":"Haynes R, Judge PK, Staplin N, et al. Effects of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease. Circulation. 2018;138:1505\u201314.","journal-title":"Circulation"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-022-07421-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-022-07421-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-022-07421-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T06:23:43Z","timestamp":1715927023000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-022-07421-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,7]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["7421"],"URL":"https:\/\/doi.org\/10.1007\/s10557-022-07421-0","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,7]]},"assertion":[{"value":"28 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study complied with the Declaration of Helsinki and was approved by the ethics committee of Kaohsiung Chang Gung Memorial Hospital (number: 202100981B0C501).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was waived by IRB due to the retrospective study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Written informed consent was waived by IRB due to the retrospective study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}